⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15822863 | 0.75 | LMNA (0.32) | — | |
| SCHEMBL791761 | 0.74 | — | — | |
| SCHEMBL2079223 | 0.74 | — | — | |
| SCHEMBL14938570 | 0.70 | — | — | |
| SCHEMBL3946974 | 0.70 | — | — | |
| SCHEMBL15822865 | 0.70 | MEN1 (0.33) | — | |
| SCHEMBL3936673 | 0.70 | — | — | |
| SCHEMBL8308634 | 0.69 | HSP90AA1 (0.35) | — | |
| SCHEMBL2407821 | 0.67 | NOS3 (0.37) | — | |
| SCHEMBL3713788 | 0.66 | LMNA (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10383874-B2 | Arylquinazolines | MERK PATENT GMBH (DE) | 2019-08-20 | — | — | US | claimed |
| US-20190142833-A1 | ARYLQUINAZOLINES | MERCK PATENT GMBH (DE) | 2019-05-16 | — | — | US | claimed |
| US-10172859-B2 | Arylquinazolines | MERCK PATENT GMBH (DE) | 2019-01-08 | — | — | US | claimed |
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| EP-2994467-B1 | ARYLQUINAZOLINES | MERCK PATENT GMBH (DE) | 2018-08-01 | — | — | EP | claimed |
| US-20170290836-A1 | ARYLQUINAZOLINES | MERCK PATENT GMBH (DE) | 2017-10-12 | — | — | US | claimed |
| US-20160083401-A1 | ARYLQUINAZOLINES | MERCK PATENT GMBH (DE) | 2016-03-24 | — | — | US | claimed |
| EP-2994467-A1 | ARYLQUINAZOLINES | Merck Patent GmbH (DE) | 2016-03-16 | — | — | EP | claimed |
| EP-2271650-B1 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | claimed |
| WO-2014183850-A1 | ARYLQUINAZOLINES | MERCK PATENT GMBH (DE) | 2014-11-20 | — | — | WO | claimed |
| EP-2271650-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2011-01-12 | — | — | EP | claimed |
| US-7863291-B2 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-04 | — | — | US | claimed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | claimed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | claimed |
| WO-2009131926-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-29 | — | — | WO | claimed |
| EP-0540143-B1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 2003-02-05 | — | — | EP | claimed |
| US-5658907-A | THIOUREA VIRICIDES | MEDIVIR A/B (SE) | 1997-08-19 | — | — | US | claimed |
| EP-0761673-A1 | Cephalosporin derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-12 | — | — | EP | claimed |
| EP-0540143-A2 | Compounds and methods for inhibition of HIV and related viruses | Medivir Aktiebolag (SE) | 1993-05-05 | — | — | EP | claimed |
| WO-1993003022-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1993-02-18 | — | — | WO | claimed |